Company Overview and News
Aug 22 (Reuters) - Curacao’s Isla refinery continues operating at a minimum level as it waits for the resolution of a legal dispute between Venezuela’s state-run PDVSA and ConocoPhillips to restore crude supplies to the plant, three sources close to the matter said.
For context, 2Q18 distributions refer to the distributions that will be paid in 3Q18 as a result of operational performance in 2Q18. The pie charts below reflect the Q/Q changes to distributions, comparing 2Q18 with 1Q18. For this exercise, we included Williams Partners (former ticker WPZ), which declared a distribution on July 23rd with a record date of August 3rd and was subsequently removed from both indices due to its merger with Williams Companies Inc.
BKEP AMID RMP EPD ALJ SEP ANDX HCLP AM GNE EQM WPZ WMB MMP PAA GEL MPLX VNOM PSXP TCP ALDW SHLX DM WES CVRR SPH GNE NS
HOUSTON, Aug 20 (Reuters) - Venezuela's PDVSA and NuStar Energy LP have reached an agreement over outstanding storage fees, allowing the state-run company to resume use of a key storage terminal in the Caribbean, the U.S. energy firm said on Monday.
HOUSTON (Reuters) - Venezuela’s state-run PDVSA and NuStar Energy LP have reached a payment agreement over outstanding storage fees at Statia terminal in the Caribbean island of St Eustatius, the U.S. oil company said on Monday.
FANG, which stands for Facebook, Amazon, Netflix and Google, was coined by the "Mad Money" host himself to refer to the group of high-performing tech stocks. But given Thursday's market moves, Cramer thinks WANG – Walmart, Apple, Netflix and Google – might be the new group to watch.
LRCX GEC GE RDS.B RDS.A RDSB RDSA MTCH EBIX AMAT RYDBF AEP GNE NS RYDAF
2018-08-16 cnbc - 2
Royal Dutch Shell: "Everyone hates the oils, which means it is time to buy the oils because oil's going from $70 to $80. Everybody is all crazy about them. Royal Dutch is really good."
FOXF LRCX RDS.B RDS.A RDSB SRPT RDSA SNEJF MPC DNR EBIX AMAT RYDBF URI NS SNE RYDAF
NuStar Energy L.P. (NS - Free Report) recently reported second-quarter 2018 earnings per limited partner unit of 15 cents, missing the Zacks Consensus Estimate of 21 cents due to a fall in Storage segment income caused by increased operating costs. However, the reported figure surged from the year-ago earnings of 5 cents per unit, due to higher contributions from the partnership’s Permian Crude System.
COP CQP LNG CNQ NS UCTI LNG UCTT
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NS / NuStar Energy L.P. on message board site Silicon Investor.
as of ET